Category Archives: Replicel

Brief Items of Interest, March 2017

Hair loss news first:

— The biggest news this past month is from Canada based Replicel (Japan based Shiseido’s partner), a company that I have covered dozens of times on this blog before. They just released 5-year safety data for “a high-dose of dermal sheath cup cells (DSCC) for patients with pattern baldness due to androgenetic alopecia”, which is basically their RCH-01 product. Since the injected cells are a patient’s own cells (i.e., autologous), the positive safety results are not surprising. In regards to efficacy (on a small sample size of 19 test patients –> 10 male and 9 female): “an overall stabilization of hair loss was observed among all the patients treated per protocol”. The best 10 respondents witnessed a sustained 4.2 percent increase over baseline hair density at 24 months after injection. Will be interesting to see their 5-year post injection efficacy results, since current data only covered 2 years post injection results.

The scientists involved theorize that rather than one large dose, many small doses spread over some time period will result in even superior outcomes. Results will also improve as they learn more about optimum depth of injections, make use of their new proprietary injection device, and conduct gene expression analysis. FYI — I am much more interested in Shiseido than in Replicel, but unfortunately the former never makes any announcements (at least not in English newspapers), while the latter has in recent months been making a significant announcement almost every single week.

— I covered Dr. Manabu Ohyama on this blog before. This week he published an important study that could help advance research into overcoming the difficulties associated with the preparation of trichogenic human dermal papilla cells (and, as a result, help in the bioengineering of hair follicles). The study is too technical for me to understand without devoting many hours of time. However, I found it quite interesting that in the report, they devote a large section to Minoxidil. Interesting quote regarding how Minoxidil works:

“Minoxidil is a clinically used hair growth promoter that enhances hair KC (keratinocyte) proliferation and activates hDP cells to induce growth factors. IGF-1 is among these growth factors, and has been shown to exhibit a potent hair elongation effect.”

— I have covered Australian company Cellmid a few times on this blog before, usually very briefly since I am a skeptic about any purported benefits of their hair growth product beyond modest regrowth at best. However, today I read that the company’s CEO Maria Halasz purchased 400,000 shares of Cellmid (at a cost of $11,200) and now holds a total of 27.3 million shares. I guess either she really believes in their hair loss product (which inhibits fibroblast growth factor-5 = FGF-5), or she believes that she will be able to sell her stake at a higher price irrespective of how well the product ends up doing. The company has made several important announcements on Twitter recently, and saw phenomenal sales growth in the last quarter of 2016.

Aclaris Therapeutics update (h/t commentator “J_van”).

— A great testimonial from Dr. Sanusi Umar’s hair transplant patient. Majority of grafts used were from body hair, especially from the beard region.

Interesting new video from hair transplant surgeon Dr. John Cole.

James Nesbitt and his hair transplants.

And now on to medical items of interest:

Terminal cancer remission in 1/3 of patients after new gene therapy treatment.

New blood test for early cancer detection.

Cambridge scientists create first self-developing embryo from stem-cells. In mice.

3D printed fully functional blood vessel network created via using an ultra-fast bioprinting system.

Interesting stem cell work from Japan/RIKEN (h/t commentator “baldings”).

Editas, Allergan and gene editing for eye diseases.

— Update on DIY biohacking:

Replicel CEO Lee Buckler Addresses us Directly

I have always assumed that Replicel probably gets a ton more questions on social media about its hair loss related work versus its tendon repair and skin generation related work. Nevertheless, I do not think that the company’s CEO Lee Buckler ever addressed us hair loss sufferers directly until today (thanks to commentator “ayush” for posting that link). The main point from the video address by Mr. Buckler –> earliest possible release of the company’s RCH-01 hair loss product is in 2018, and that is predicated upon successful clinical trial results from the company’s much larger Japanese partner Shiseido. I suspect that Mr. Buckler got tired of getting the same question over and over again about when they will release the hair loss product and finally decided to release this latest video. It seems like Replicel’s disagreement with Shiseido from last year is not hurting the two companies’ long-term collaboration.

Replicel and Mr. Buckler have been extremely busy in recent weeks. Just from the past week, you can read and listen to two new interviews from the CEO:

And there was also a detailed favorable report on Replicel in Zacks Investment Research two weeks ago as well a “brokered private placement” of common shares by the company.

Also make sure to read my January 2017 brief items of interest post’s first paragraph for more recent news on Replicel.